Following the successful completion of preclinical development for their HemoSystem blood purification platform, hemotune closed a CHF 14 million Series B2 round. The funds will be used to move into clinical trials.
Following the successful completion of preclinical development for their HemoSystem blood purification platform, hemotune closed a CHF 14 million Series B2 round. The funds will be used to move into clinical trials.